On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend placing six peptides on the agency's 503A Bulks List, the roster of substances that licensed compounding pharmacies may use to prepare individualized prescriptions. The panel rejected a seventh peptide, emideltide, by a 7-6 margin. The recommendation ran directly counter to the FDA's own scientific staff, who told the committee that none of the seven substances under review had adequate human safety or efficacy data, and it arrived inside a political campaign led by HHS Secretary Robert F. Kennedy Jr. to dismantle restrictions imposed under the prior administration. ABC News reported that FDA staff scientists had unanimously opposed every peptide being added to the list, citing a lack of solid clinical trial data, inconsistent recipes from batch to batch, and the risk the compounds could trigger harmful immune reactions.
Russell Wesdyk, associate director for regulatory affairs in the FDA's drug center, told the panel that names like TB-500 carry no legal meaning as pharmaceutical ingredients in the United States. "There's no way to know what the substance actually is, was or will be tomorrow because that name has no legal meaning," Wesdyk said, according to Fortune. His warning addressed a practical problem no advisory vote resolves: without an official monograph, a compounding pharmacist filling a prescription for BPC-157 or KPV cannot verify which chemical form, salt, or impurity profile the patient will receive. The recommendation opens a legal channel for substances the agency cannot yet define.
The vote is advisory. The FDA is not required to follow it, and formal placement on the 503A Bulks List would require notice-and-comment rulemaking, a process that typically takes months or years. Fortune reported that FDA-watchers consider the likeliest near-term outcome a temporary enforcement-discretion policy reassuring pharmacies they will not be targeted while the review proceeds. Kennedy, who oversees the FDA as HHS secretary, holds final authority to accept or reject the panel's advice. No timeline for that decision has been announced.
Figure 1: Regulatory pathway and advisory committee evaluation framework for Inside the FDA Vote: How the 'RFK Jr. Effect' Reshaped Peptide Policy.
The panel that voted
The committee that delivered the 8-6 tally did not resemble prior iterations of the PCAC. Before the July meeting, more than half a dozen members with connections to the peptide industry were added to the roster, including physicians, pharmacists, and consultants who work in or sell products from the field. ABC News reported that six of the eight recently appointed members run clinics that offer peptides. Panel members with academic backgrounds rather than peptide-industry ties voted predominantly against listing the substances. The first vote, on BPC-157, broke along the lines of when members had been appointed, Politico reported, with Kennedy-appointed members favoring listing and longer-tenured members opposing it.
Kennedy has described himself as a "big fan" of peptides and vowed to overturn restrictions put in place under President Biden. In February 2026, he announced that approximately 14 of the 19 peptides then on the FDA's Category 2 restricted compounding list would be moved back to Category 1, restoring a legal pathway for compounding pharmacies to prepare them. The July panel vote represented the next procedural step in that reversal, applying the same logic to injectable peptides that had been barred from pharmacy production entirely.
The six peptides the panel recommended for listing are BPC-157, TB-500, KPV, Semax, Epitalon, and MOTS-C. None appears on the current roster of fda approved peptides. Drug manufacturers opposed the listing, arguing it creates a loophole around the years of clinical trials normally required before a medication reaches patients.
Scientific dissent and the harm-reduction argument
The FDA group met on July 23 and 24 to vote on whether compounding pharmacies could legally dispense certain peptides, Time reported, in a session spanning more than 18 hours of presentations and discussion. FDA career scientists told the committee that, for the seven peptides under review, the agency located only rat studies. No adequate human trials demonstrating safety or efficacy were identified. Scientists flagged potential adverse effects including heart toxicity, infections, pancreatitis, serious immune responses, and melanoma risk.
Advisers who voted in favor framed their support as a harm-reduction measure. They argued that patients will seek these substances regardless of FDA restrictions and that a regulated compounding channel is safer than the current market, where the only route to unapproved peptides runs through online vendors labeling products for "research use" with no physician oversight. That argument addresses a real regulatory gap: consumers asking are peptides legal encounter a patchwork in which the same molecule is a research chemical in one context and a compounded prescription in another. Proponents of the listing framed compounding as a step to reduce demand for grey market peptides sourced from overseas manufacturers operating outside U.S. quality oversight.
Safety advocates outside the panel worried that patients would mistake a spot on the compounding list for an official stamp of approval. The distinction carries weight beyond domestic borders. A peptide manufactured in a facility inspected under one country's good-manufacturing-practice rules and compounded in a U.S. pharmacy under Section 503A still lacks the clinical dossier that would satisfy either the FDA or Pacific-market regulators reviewing the same molecule for therapeutic use. The vote resolves an American access question without settling the scientific one.
What the agency does with the recommendation
A consumer watchdog group has asked the HHS Office of Inspector General to examine potential conflicts of interest among panel members who voted for broader access while holding financial stakes in peptide sales or telehealth platforms. The OIG has not announced whether it will open a review.
The FDA will review the votes, the recorded discussion, and public comments before issuing a decision on each peptide individually. Formally adding the substances to the compounding list requires new regulations drafted through notice-and-comment rulemaking. Until that process concludes, the peptides remain restricted, and pharmacies that compound them risk enforcement action unless the agency issues interim guidance shielding them from prosecution. Kennedy's February reclassification and the July advisory vote together represent the most significant loosening of federal peptide restrictions since the Category 2 designations were imposed in 2023. Whether the final agency decision tracks the panel's recommendation or reasserts the scientific staff's objections remains undetermined. The vote was a recommendation. The rule has not been written.
